Some recommend scoring solid intraductal carcinoma as Gleason 5, but the cancer is linked to significantly poorer outcomes.

with novel GenAI tools to transform patient experience." "Call them what you may — decentralized trials, virtual trials, hybrid trials — DCTs are here to stay," wrote Dr. Nimita Limaye, IDC ...

senior vice president for Patient and Site Centric Solutions at IQVIA. This report is IDC’s first assessment of both DCT technology solutions and consulting services in life science R&D.